These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

224 related articles for article (PubMed ID: 29066973)

  • 1. From Resistance to Sensitivity: Insights and Implications of Biphasic Modulation of Autophagy by Sunitinib.
    Abdel-Aziz AK; Abdel-Naim AB; Shouman S; Minucci S; Elgendy M
    Front Pharmacol; 2017; 8():718. PubMed ID: 29066973
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Sunitinib malate for the treatment of metastatic renal cell carcinoma and gastrointestinal stromal tumors.
    Adams VR; Leggas M
    Clin Ther; 2007 Jul; 29(7):1338-53. PubMed ID: 17825686
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mechanisms of sunitinib resistance in gastrointestinal stromal tumors harboring KITAY502-3ins mutation: an in vitro mutagenesis screen for drug resistance.
    Guo T; Hajdu M; Agaram NP; Shinoda H; Veach D; Clarkson BD; Maki RG; Singer S; Dematteo RP; Besmer P; Antonescu CR
    Clin Cancer Res; 2009 Nov; 15(22):6862-70. PubMed ID: 19861442
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Combination of pimitespib (TAS-116) with sunitinib is an effective therapy for imatinib-resistant gastrointestinal stromal tumors.
    Teranishi R; Takahashi T; Obata Y; Nishida T; Ohkubo S; Kazuno H; Saito Y; Serada S; Fujimoto M; Kurokawa Y; Saito T; Yamamoto K; Yamashita K; Tanaka K; Makino T; Nakajima K; Hirota S; Naka T; Eguchi H; Doki Y
    Int J Cancer; 2023 Jun; 152(12):2580-2593. PubMed ID: 36752576
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical efficacy of second-generation tyrosine kinase inhibitors in imatinib-resistant gastrointestinal stromal tumors: a meta-analysis of recent clinical trials.
    Wu L; Zhang Z; Yao H; Liu K; Wen Y; Xiong L
    Drug Des Devel Ther; 2014; 8():2061-7. PubMed ID: 25378911
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ripretinib versus sunitinib in patients with advanced gastrointestinal stromal tumor after treatment with imatinib: a plain language summary of the phase 3 INTRIGUE trial.
    Symcox M; Jones RL
    Future Oncol; 2023 Nov; 19(36):2383-2393. PubMed ID: 37594164
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Resistance to sunitinib in renal clear cell carcinoma results from sequestration in lysosomes and inhibition of the autophagic flux.
    Giuliano S; Cormerais Y; Dufies M; Grépin R; Colosetti P; Belaid A; Parola J; Martin A; Lacas-Gervais S; Mazure NM; Benhida R; Auberger P; Mograbi B; Pagès G
    Autophagy; 2015; 11(10):1891-904. PubMed ID: 26312386
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Advances in the treatment of gastrointestinal stromal tumours.
    Judson I; Demetri G
    Ann Oncol; 2007 Sep; 18 Suppl 10():x20-4. PubMed ID: 17761719
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The tyrosine kinase inhibitor, sunitinib malate, induces cognitive impairment in vivo via dysregulating VEGFR signaling, apoptotic and autophagic machineries.
    Abdel-Aziz AK; Mantawy EM; Said RS; Helwa R
    Exp Neurol; 2016 Sep; 283(Pt A):129-41. PubMed ID: 27288242
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Primary and secondary kinase genotypes correlate with the biological and clinical activity of sunitinib in imatinib-resistant gastrointestinal stromal tumor.
    Heinrich MC; Maki RG; Corless CL; Antonescu CR; Harlow A; Griffith D; Town A; McKinley A; Ou WB; Fletcher JA; Fletcher CD; Huang X; Cohen DP; Baum CM; Demetri GD
    J Clin Oncol; 2008 Nov; 26(33):5352-9. PubMed ID: 18955458
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Developments in targeted therapy of advanced gastrointestinal stromal tumors.
    Rutkowski P; Symonides M; Zdzienicki M; Siedlecki JA
    Recent Pat Anticancer Drug Discov; 2008 Jun; 3(2):88-99. PubMed ID: 18537751
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sunitinib: a novel tyrosine kinase inhibitor. A brief review of its therapeutic potential in the treatment of renal carcinoma and gastrointestinal stromal tumors (GIST).
    Le Tourneau C; Raymond E; Faivre S
    Ther Clin Risk Manag; 2007 Jun; 3(2):341-8. PubMed ID: 18360643
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long-term exposure of gastrointestinal stromal tumor cells to sunitinib induces epigenetic silencing of the PTEN gene.
    Yang J; Ikezoe T; Nishioka C; Takezaki Y; Hanazaki K; Taguchi T; Yokoyama A
    Int J Cancer; 2012 Feb; 130(4):959-66. PubMed ID: 21445973
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sunitinib in the management of gastrointestinal stromal tumours (GISTs).
    Hopkins TG; Marples M; Stark D
    Eur J Surg Oncol; 2008 Aug; 34(8):844-850. PubMed ID: 18082353
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Activity and safety of the multi-target tyrosine kinase inhibitor cabozantinib in patients with metastatic gastrointestinal stromal tumour after treatment with imatinib and sunitinib: European Organisation for Research and Treatment of Cancer phase II trial 1317 'CaboGIST'.
    Schöffski P; Mir O; Kasper B; Papai Z; Blay JY; Italiano A; Benson C; Kopeckova K; Ali N; Dileo P; LeCesne A; Menge F; Cousin S; Wardelmann E; Wozniak A; Marreaud S; Litiere S; Zaffaroni F; Nzokirantevye A; Vanden Bempt I; Gelderblom H
    Eur J Cancer; 2020 Jul; 134():62-74. PubMed ID: 32470848
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tyrosine kinase inhibition in renal cell carcinoma and gastrointestinal stromal tumours: case reports.
    Schöffski P; Bukowski R; Flodgren P; Ravaud A
    Ann Oncol; 2009 May; 20 Suppl 1():i25-i30. PubMed ID: 19430005
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Potential new therapy of Rapalink-1, a new generation mammalian target of rapamycin inhibitor, against sunitinib-resistant renal cell carcinoma.
    Kuroshima K; Yoshino H; Okamura S; Tsuruda M; Osako Y; Sakaguchi T; Sugita S; Tatarano S; Nakagawa M; Enokida H
    Cancer Sci; 2020 May; 111(5):1607-1618. PubMed ID: 32232883
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Expanding the boundaries of clinical practice: building on experience with targeted therapies.
    Sternberg CN
    Ann Oncol; 2009 May; 20 Suppl 1():i1-6. PubMed ID: 19430002
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tyrosine kinase inhibitors in the treatment of unresectable or metastatic gastrointestinal stromal tumors.
    Nishida T; Doi T; Naito Y
    Expert Opin Pharmacother; 2014 Oct; 15(14):1979-89. PubMed ID: 24990162
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Complementary activity of tyrosine kinase inhibitors against secondary kit mutations in imatinib-resistant gastrointestinal stromal tumours.
    Serrano C; Mariño-Enríquez A; Tao DL; Ketzer J; Eilers G; Zhu M; Yu C; Mannan AM; Rubin BP; Demetri GD; Raut CP; Presnell A; McKinley A; Heinrich MC; Czaplinski JT; Sicinska E; Bauer S; George S; Fletcher JA
    Br J Cancer; 2019 Mar; 120(6):612-620. PubMed ID: 30792533
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.